Guardant Health (GH) closed at $178.80 on October 30, 2026, down 3.5% from the previous close, on volume of 1,351,702 shares (30-day average 1,754,086).
Data as of October 30, 2026.
30-Oct-2026
Business Wire (Thu, 29-Oct 8:05 AM ET)
Market Chameleon (Wed, 21-Oct 7:20 AM ET)
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Business Wire (Tue, 20-Oct 9:02 AM ET)
Business Wire (Thu, 15-Oct 4:01 PM ET)
Business Wire (Thu, 15-Oct 8:05 AM ET)
Business Wire (Thu, 8-Oct 4:12 PM ET)
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
Business Wire (Thu, 8-Oct 4:05 PM ET)
Business Wire (Mon, 5-Oct 11:27 AM ET)
Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Business Wire (Mon, 14-Sep 4:05 PM ET)
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health trades on the NASDAQ stock market under the symbol GH.
As of October 30, 2026, GH stock price declined to $178.80 with 1,351,702 million shares trading.
GH has a beta of 1.21, meaning it tends to be more sensitive to market movements. GH has a correlation of 0.06 to the broad based SPY ETF.
GH has a market cap of $23.99 billion. This is considered a Large Cap stock.
Last quarter Guardant Health reported $335 million in Revenue and -$.42 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.04.
In the last 3 years, GH traded as high as $191.05 and as low as $15.81.
The top ETF exchange traded funds that GH belongs to (by Net Assets): VTI, VB, VBK, VXF, IWP.
GH has outperformed the market in the last year with a price return of +93.5% while the SPY ETF gained +12.3%. GH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.4% and +12.7%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
GH support price is $179.06 and resistance is $191.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GH shares will trade within this expected range on the day.
